Document is current
Any future updates will be listed below
-
Authors
Cole, Frances M.
Laszlo, George S.
Lunn-Halbert, Margaret C. https://orcid.org/0000-0003-0527-5575
Kehret, Allie R. https://orcid.org/0000-0002-3186-566X
Zweidler-McKay, Patrick A. https://orcid.org/0000-0001-6621-523X
Rodríguez-Arbolí, Eduardo
Wu, David
Nyberg, Kyle
Li, Junyang
Lim, Sheryl Y. T. https://orcid.org/0000-0002-2606-9220
Pettenger-Willey, Camryn M. https://orcid.org/0000-0002-3203-3558
Lakshmikanthan, Sribalaji
Walter, Roland B. https://orcid.org/0000-0002-9268-3341
-
Funding
Funding for this research was provided by:
ImmunoGen
- License Information
-
More Information
Article History
Received: 12 December 2024
Revised: 21 February 2025
Accepted: 13 March 2025
First Online: 21 March 2025
Competing interests
: PAZ-M reports previous employment with ImmunoGen (now AbbVie). SL reports employment with AbbVie. RBW received laboratory research grants and/or clinical trial support from Celgene/Bristol Myers Squibb, ImmunoGen/AbbVie, Janssen, Jazz, Kite, Kura, Pfizer, and Vor Biopharma, and has been a consultant to Wugen. The other authors declare no competing financial interests.
: All laboratory research described in this article was conducted under a broad research protocol approved by the Fred Hutchinson Cancer Center Institutional Review Board (Fred Hutch IRB; protocol #9045). Biospecimens from adults with AML were obtained from an institutional repository under protocol #1690 approved by the Fred Hutch IRB; all patients provided written informed consent for sample collection and use for research. All methods were performed in accordance with the relevant guidelines and regulations.
